117 related articles for article (PubMed ID: 22228793)
1. Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.
Stelter L; Evans MJ; Jungbluth AA; Zanzonico P; Ritter G; Ku T; Rosenfeld E; Bomalaski JS; Old L; Larson SM
J Nucl Med; 2012 Feb; 53(2):281-6. PubMed ID: 22228793
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.
Stelter L; Fuchs S; Jungbluth AA; Ritter G; Longo VA; Zanzonico P; Raschzok N; Sauer IM; Bomalaski JS; Larson SM
Mol Imaging Biol; 2013 Dec; 15(6):768-75. PubMed ID: 23722880
[TBL] [Abstract][Full Text] [Related]
3. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
Tsai WB; Aiba I; Long Y; Lin HK; Feun L; Savaraj N; Kuo MT
Cancer Res; 2012 May; 72(10):2622-33. PubMed ID: 22461507
[TBL] [Abstract][Full Text] [Related]
4. In vivo responses of human A375M melanoma to a σ ligand: 18F-FDG PET imaging.
Rybczynska AA; de Bruyn M; Ramakrishnan NK; de Jong JR; Elsinga PH; Helfrich W; Dierckx RA; van Waarde A
J Nucl Med; 2013 Sep; 54(9):1613-20. PubMed ID: 23940303
[TBL] [Abstract][Full Text] [Related]
5. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
6. Amino Acid Uptake Measured by [
Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
[No Abstract] [Full Text] [Related]
7. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.
Stelter L; Evans MJ; Jungbluth AA; Longo VA; Zanzonico P; Ritter G; Bomalaski JS; Old L; Larson SM
Mol Imaging; 2013; 12(1):67-73. PubMed ID: 23348793
[TBL] [Abstract][Full Text] [Related]
8. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
Ott PA; Carvajal RD; Pandit-Taskar N; Jungbluth AA; Hoffman EW; Wu BW; Bomalaski JS; Venhaus R; Pan L; Old LJ; Pavlick AC; Wolchok JD
Invest New Drugs; 2013 Apr; 31(2):425-34. PubMed ID: 22864522
[TBL] [Abstract][Full Text] [Related]
10. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
[TBL] [Abstract][Full Text] [Related]
11. (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.
Carlino MS; Saunders CA; Haydu LE; Menzies AM; Martin Curtis C; Lebowitz PF; Kefford RF; Long GV
Eur J Cancer; 2013 Jan; 49(2):395-402. PubMed ID: 22981500
[TBL] [Abstract][Full Text] [Related]
12. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Manca A; Sini MC; Izzo F; Ascierto PA; Tatangelo F; Botti G; Gentilcore G; Capone M; Mozzillo N; Rozzo C; Cossu A; Tanda F; Palmieri G
Oncol Rep; 2011 Jun; 25(6):1495-502. PubMed ID: 21424129
[TBL] [Abstract][Full Text] [Related]
13. Arginine deiminase, a potential anti-tumor drug.
Ni Y; Schwaneberg U; Sun ZH
Cancer Lett; 2008 Mar; 261(1):1-11. PubMed ID: 18179862
[TBL] [Abstract][Full Text] [Related]
14. Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor.
Tseng JR; Stuart D; Aardalen K; Kaplan A; Aziz N; Hughes NP; Gambhir SS
Neoplasia; 2011 Mar; 13(3):266-75. PubMed ID: 21390189
[TBL] [Abstract][Full Text] [Related]
15. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.
Synakiewicz A; Stachowicz-Stencel T; Adamkiewicz-Drozynska E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1517-29. PubMed ID: 24965808
[TBL] [Abstract][Full Text] [Related]
16. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
[TBL] [Abstract][Full Text] [Related]
17. High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearance.
Denoyer D; Greguric I; Roselt P; Neels OC; Aide N; Taylor SR; Katsifis A; Dorow DS; Hicks RJ
J Nucl Med; 2010 Mar; 51(3):441-7. PubMed ID: 20150254
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis imaging probe predicts early chemotherapy response in preclinical models: A comparative study with 18F-FDG PET.
Song S; Xiong C; Lu W; Ku G; Huang G; Li C
J Nucl Med; 2013 Jan; 54(1):104-10. PubMed ID: 23283564
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of anti-tumor activity in melanoma using arginine deiminase fused with 30Kc19α protein.
Lee H; Park G; Kim S; Son B; Joo J; Park HH; Park TH
Appl Microbiol Biotechnol; 2022 Nov; 106(22):7531-7545. PubMed ID: 36227339
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model.
Rex K; Lewis XZ; Gobalakrishnan S; Glaus C; Silva MD; Radinsky R; Burgess TL; Gambhir SS; Coxon A
Nucl Med Biol; 2013 May; 40(4):458-63. PubMed ID: 23454250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
